TOXOPLASMOSIS TREATMENT DRUGS MARKET ANALYSIS

The global toxoplasmosis treatment drugs market is estimated to be valued at US$ 3,310.1 Million in 2023 and is expected to exhibit a CAGR of 5.3% during the forecast period (2023-2030).

Analysts’ Views on the Global Toxoplasmosis Treatment Drugs Market:

Toxoplasma gondii is a worldwide protozoan parasite that infects almost all warm-blooded animals. For instance, Springer Nature published on February 10, 2021, that although human toxoplasmosis is largely latent, pregnant, and immuno-compromized patients require effective therapy. There are drugs of choice for toxoplasmosis; however, due to their side effects and/or disease stage specificity, prescription is limited. In recent years, nanomedicine has been used to overcome the limitations of conventional medicines. Here, researchers provided a state-of-the-art review of experimental treatment of toxoplasmosis using nanotechnology.

Figure 1. Global Toxoplasmosis Treatment Drugs Market Share (%), By Drug class, 2023

To learn more about this report, request sample copy

Global Toxoplasmosis Treatment Drugs Market - Drivers

Increasing awareness programs for the treatment of toxoplasmosis

Increasing awareness programs for the treatment of toxoplasmosis are expected to drive the global toxoplasmosis treatment drugs market growth over the forecast period. For instance, on January 24, 2023, TOXO-2023, scientific advance research in Toxoplasmosis announced an awareness program where TOXO-2023 had offer a unique opportunity for attendees to gain insights about the latest perspectives, updates, cutting-edge technological tools, and scientific advances in toxoplasmosis research. Toxoplasmosis is a well-known disease that results from infection with the Toxoplasma gondii parasite and more than 40 million people in the world may be infected  to raise people's awareness, the Toxoplasma parasite was explained.

Figure 2. Global Toxoplasmosis Treatment Drugs Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Toxoplasmosis Treatment Drugs Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global toxoplasmosis treatment drugs market over the forecast period owing to increasing research and development of toxoplasmosis treatment. For instance, on March 17, 2022, National Center for Biotechnology Information published a research as both treatment with sulfadiazine and artemether showed significant prolongation in time to death of the infected mice compared to the control group. Median survival days for parenteral artemether, oral artemether, sulfadiazine, and control group were 81,112 and six respectively. Expression of targeted gene in liver and brain of mice after treatment with artemether and sulfadiazine were reduced in comparison to housekeeping gene (β-tubulin gene).

Global Toxoplasmosis Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems regarding the transportation of drugs from one place to another.

However, the COVID-19 pandemic had positive impact on the global toxoplasmosis treatment drugs market, due to not consider as risk factor of toxoplasmosis for COVID-19. For instance, according to an article published by BioMed Central Ltd on September 28, 2021 explained that Toxoplasmosis is currently not considered a risk factor for COVID-19, and Toxoplasma-infected individuals are neither informed about their higher risk nor prioritized in vaccination programs. As toxoplasmosis affects a large segment of the human population, its impact on COVID-19-associated effects on public health could be considerable. The primary objective of this study was to determine whether latent toxoplasmosis affects the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the progression of coronavirus disease 2019 (COVID-19). In order to achieve this, it is necessary to consider the likelihood that COVID-19 will be diagnosed, the severity of the disease's course, and the presence of particular disease symptoms.

Global Toxoplasmosis Treatment Drugs Market Segmentation:

The global toxoplasmosis treatment drugs market report is segmented into drug class, indication, route of administration, distribution channel, and region.

Based on drug class, the global toxoplasmosis treatment drugs market is segmented into pyrimethamine, spiramycin, leucovorin, sulfadiazine, folic acid, and others. Out of which, the pyrimethamine drug class segment is expected to dominate the market due to research and development in drugs for the treatment of toxoplasmosis.

Based on indication, the global toxoplasmosis treatment drugs market is segmented into chronic toxoplasmosis infection and acute toxoplasmosis infection. Out of which, the acute toxoplasmosis infection segment is expected to dominate the market due to increasing treatment for toxoplasmosis.

Based on route of administration, the global toxoplasmosis treatment drugs market is segmented into parenteral and oral. Out of which, the oral segment is expected to dominate the market due to increased treatments and easiest route for administration of drug for treating toxoplasmosis.

Based on distribution channel, the global toxoplasmosis treatment drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. Out of which, the hospital pharmacies segment is expected to dominate the market due to the easy accessibility and immediate access to treatments.

Among segmentation, the drug class segment is expected to dominate the global toxoplasmosis treatment drugs market. For instance, on May 5, 2023, Springer Nature Limited published an article explaining the first-choice therapy for the treatment of toxoplasmosis is still the combination of pyrimethamine (PYR) and sulfadiazine (SDZ). Although this therapy is usually effective, failures in the long-term treatment of chorioretinitis, congenital toxoplasmosis, and mainly toxoplasmic encephalitis. The lack of response to treatment could be related to pharmacological parameters (drug intolerance, poor adherence, and malabsorption) and/or due to infection with drug-resistant parasites.

Global Toxoplasmosis Treatment Drugs Market Cross Sectional Analysis:

Increasing treatments for toxoplasmosis in the U.S. is expected to drive the growth of the drug class type segment in the region. For instance, on May 27, 2021, National Center for Biotechnology Information explained that inorganic nanoparticles (NPs) may also be a source of additional and successful treatments for Toxoplasma gondii infections. According to the study, in vitro anti-Toxoplasma activity of gold, silver, and platinum nanoparticles was promising and undetectable host cell damage was absent. The assessment using a fluorescent probe offered concrete proof that the use of nanoparticles during therapy boosted ROS generation, which ultimately contributed to parasite death. Others have demonstrated how DNA damage and oxidative stress may be brought on by silver nanoparticles (AgNPs), which have the greatest range of biomedical uses of any nanoparticle.

Global Toxoplasmosis Treatment Drugs Market: Key Developments

On October 26, 2021, National Institute of Allergy and Infectious Diseases (NIAID) announced Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected patients. Patients take pyrimethamine or placebo three times a week. Patients also take leucovorin calcium orally three times weekly. Enrollment occurs over approximately 12 months. All patients are followed on study until a common study close-out date and final analysis of the study. It is anticipated that this common close-out will occur when the mean duration of time on study therapy will be 3 years. Patients receive a loading dose of pyrimethamine or placebo, plus of leucovorin calcium which was effective treatment for toxoplasmosis.

On March 20, 2020, Dr. Reddy’s Laboratories Ltd, a pharmaceutical company announced the launch of Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (FDA). This product is the only AB-rated generic version Daraprim (pyrimethamine) tablets approved by the U.S. FDA. Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.

Global Toxoplasmosis Treatment Drugs Market: Key Trends

Increasing research and development in toxoplasmosis treatment

Increasing research and development in toxoplasmosis treatment can drive the market growth. On June 22, 2021, National Center for Biotechnology Information explained Triptanthrin appears to be an attractive candidate for the treatment of Toxoplasma gondii infection. This natural alkaloid compound and its derivatives are thought to be inhibitors of T. gondii. Considering parasite growth inhibition and host cell cytotoxicity, research showed that alcohol analogues in particular are promising targets for further research for effective treatment programs. Triptanthrin is considered as a potential therapeutic agent mainly due to its structural simplicity and easy synthesis using various starting materials and methods. In addition, tryptanthrin appears to be well absorbed through the intestinal epithelial cell layer and its transepithelial transport is governed by passive diffusion. Research demonstrated a reduction in oxidative damage in hepatocytes after tryptanthrine pretreatment, which effectively reduced ROS production and mitochondrial dysfunction.

Global Toxoplasmosis Treatment Drugs Market: Restraints

Complications with toxoplasmosis treatment

The complications with toxoplasmosis treatment is expected to hamper the global toxoplasmosis treatment drugs market growth. For instance, on August 2, 2022, Cleveland Clinic published an article explaining if a patient contracts toxoplasmosis while pregnant or just before becoming pregnant, the parasite may transmit from the mother to the fetus through the placenta. Due to this, there is a higher chance of miscarriage, stillbirth, or major health issues for the unborn kid. Born with toxoplasmosis increases the risk of vision issues, blindness, developmental delays, and learning disabilities.

To counterbalance this restraint, treatments should be introduced to avoid the transmission of parasite and to treat patients.

Global Toxoplasmosis Treatment Drugs Market - Key Players

The major players operating in the global toxoplasmosis treatment drugs market include Vyera Pharmaceuticals LLC, Taj Accura Pharmaceuticals Ltd, Mangalam Drugs and Organics Ltd, Cerovene Healthcare PVT LTD, Greenstone LLC, Amneal Pharmaceuticals, Inc., Turing Pharmaceuticals, Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd, and Baxter International Inc.

Global Toxoplasmosis Treatment Drugs Market - Definition

Toxoplasmosis is a worldwide parasitic disease infecting about one third of humans, with possible severe outcomes in neonates and immunocompromised patients. Despite continuous and successful efforts to improve diagnosis, therapeutic schemes have barely evolved since many years.